Peptide Atlas · Peptide
Thymopentin (TP5)
In a double-blind trial in 100 patients with moderate to severe atopic dermatitis, six weeks of daily subcutaneous thymopentin reduced clinical severity, itching and redness more than placebo.
- emerging
- provisional
- PubChem 451417
- 2 citations
- 0 discussions
- 0 followers
- RKDVY
- TP5
- Timunox
- thymopoietin (32-36)
What the evidence says
six tiers, never blendedemerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Negative findings
failure is informationNobody has filed a failure yet. Failures are information; this list is waiting for an honest one.